Exane BNP Paribas downgraded Philips from Outperform to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2025 | Neutral → Outperform | Exane BNP Paribas | |
| 2/20/2025 | Neutral → Buy | UBS | |
| 10/29/2024 | Underperform → Hold | Jefferies | |
| 5/13/2024 | Mkt Perform → Outperform | Bernstein | |
| 5/7/2024 | Underperform → Neutral | Exane BNP Paribas | |
| 4/30/2024 | Sell → Neutral | UBS | |
| 4/30/2024 | Underweight → Neutral | JP Morgan | |
| 2/7/2024 | Outperform → Underperform | Exane BNP Paribas |
May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa
Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.Mr Marnix van Ginneken proposed for reappointment as member of Philips' Board of Management. February 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment. Mr David Pyott (British/American, 1953) will retire from Philips' Supervisory Board at the end of the Annu
January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business that was temporarily led by Bert van Meurs, who will continue to lead Philips' Image Guided Therapy business. Ms. Xue and Mr. Van Meurs will be jointly responsible for the Diagnosis & Treatment segment. Ms. F
May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in USUpdated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs,
March 24, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)) today announced it has convened the Annual General Meeting of Shareholders (AGM) 2025 and published the agenda with explanatory notes.As previously announced, the agenda includes: Proposal to appoint Mr Bob White (American, 1962) as a new member of the Supervisory Board, with effect from May 8, 2025.Proposals to re-appoint Ms Indra Nooyi (American, 1955) and Ms Chua Sock Koong (Singaporean, 1957) as members of the Supervisory Board, with effect from May 8, 2025.Proposal to re-appoint Mr Marnix van Ginneken (Dutch, 1973) as a member of the Philips Board of Management, with effect from May 8, 2025. The agenda fu
February 19, 2025Full Year and Q4 Group performance highlights Sales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in ChinaComparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in ChinaIncome from operations was EUR 529 million in 2024; EUR 199 million in Q4Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4Net cash flow from operating activities was EUR 1,569 million in 2024; EUR 1,459 million in Q4Free cash flow was EUR 906 million in 2024; EUR 1,285 million in Q4Finalized Philips Respironics recall-related me
Exane BNP Paribas upgraded Philips from Neutral to Outperform
UBS upgraded Philips from Neutral to Buy
Jefferies upgraded Philips from Underperform to Hold
Collaboration designed to enhance health awareness for moms during pregnancy and improve health outcomes Aggregated analytics data and surveys from app will help provide maternal health insights Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, and March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, today announced a collaboration aimed at improving maternal health education through the Philips Avent Pregnancy+ app. Philips will integrate essential March of Dimes content into the app to help improve health literacy and create awareness for topics such as preparing for a Neonatal Intensive Care Unit (NICU) stay, pret
May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. T
May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real timeCatheter offers enhanced procedural guidance without the need for general anesthesia, supporting more efficient and patient-friendly care for structural heart disease Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United State
SD - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13D - KONINKLIJKE PHILIPS NV (0000313216) (Subject)